Nkarta, Inc.
NKTXNkarta is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf natural killer (NK) cell therapies.
Table of contents
Earnings
Next report
Aug 11, 2026 (In 4 weeks)Competitors
By market cap
Profile
Nkarta is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf natural killer (NK) cell therapies. The company leverages a proprietary modular engineering platform to create CAR NK cells designed to be more accessible and better tolerated than traditional autologous T-cell therapies. Its primary focus is on treating B-cell mediated autoimmune diseases by targeting the CD19 antigen to deplete pathogenic B cells.
Nkarta is a pioneer in allogeneic CAR NK therapies, utilizing a proprietary platform that includes mbIL-15 for cell persistence and internal cGMP manufacturing to ensure scalability.
Questions, answered.
- What is Nkarta, Inc.'s market cap?
- Nkarta, Inc. (NKTX) has a market capitalization of $229.7M and trades on NASDAQ.
- Who are Nkarta, Inc.'s competitors?
- Nkarta, Inc.'s key competitors include Kyverna Therapeutics, Cabaletta Bio, Fate Therapeutics, and others. These companies compete in similar markets and product categories.
- Who does Nkarta, Inc. partner with?
- Nkarta, Inc.'s notable partners include National University of Singapore, St. Jude Children’s Research Hospital, Inc., Columbia University Irving Medical Center, and others.
- Where is Nkarta, Inc. headquartered?
- Nkarta, Inc. is headquartered in United States of America and employs approximately 150 people. It has been publicly traded since 2020.